Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
Neha Prakash,Chelsea Caspell-Garcia,Christopher Coffey,Andrew Siderowf,Caroline M Tanner,Karl Kieburtz,Brit Mollenhauer,Douglas Galasko,Kalpana Merchant,Tatiana Foroud,Lana M Chahine,Daniel Weintraub,Cindy Casaceli,Ray Dorsey,Renee Wilson,Margaret Herzog,Nichole Daegele,Vanessa Arnedo,Mark Frasier,Todd Sherer,Ken Marek,Samuel Frank,Danna Jennings,Tanya Simuni,Parkinson's Progression Markers InitiativeSteering Committee,Study Cores,Site Investigators,Coordinators,Industry and Scientific Advisory Board,Kenneth Marek,John Seibyl,Caroline Tanner,Duygu Tosun-Turgut,Leslie Shaw,John Trojanowski,Andrew Singleton,Arthur Toga,Werner Poewe,Kathleen Poston,Sohini Chowdhury,Catherine Kopil,Cynthia Casaceli,Sugi Mahes,Christina Salerno,Karen Crawford,Paola Casalin,Giulia Malferrari,Mali Gani Weisz,Avi Orr-Urtreger,Thomas Montine,David Russell,Nabila Dahodwala,Nir Giladi,Stewart Factor,Penelope Hogarth,David Standaert,Robert Hauser,Joseph Jankovic,Marie Saint-Hilaire,Irene Richard,David Shprecher,Hubert Fernandez,Katrina Brockmann,Liana Rosenthal,Paolo Barone,Alberto Espay,Dominic Rowe,Karen Marder,Anthony Santiago,Susan Bressman,Shu-Ching Hu,Stuart Isaacson,Jean-Christophe Corvol,Javiar Ruiz Martinez,Eduardo Tolosa,Yen Tai,Marios Politis,Debra Smejdir,Linda Rees,Karen Williams,Farah Kausar,Whitney Richardson,Diana Willeke,Shawnees Peacock,Beatrice Heim,Anat Mirelman,Barbara Sommerfeld,Alison Freed,Katrina Wakeman,Courtney Blair,Stephanie Guthrie,Leigh Harrell,Christine Hunter,Cathi-Ann Thomas,Raymond James,Grace Zimmerman,Victoria Brown,Jennifer Mule,Ella Hilt,Kori Ribb,Susan Ainscough,Misty Wethington,Madelaine Ranola,Helen Mejia Santana,Juliana Moreno,Deborah Raymond,Krista Speketer,Lisbeth Carvajal,Stephanie Carvalho,Ioana Croitoru,Alicia Garrido,Laura Marie Payne,Veena Viswanth,Lawrence Severt,Maurizio Facheris,Holly Soares,Mark A Mintun,Jesse Cedarbaum,Peggy Taylor,Kevin Biglan,Emily Vandenbroucke,Zulfiqar Haider Sheikh,Baris Bingol,Tanya Fischer,Pablo Sardi,Remi Forrat,Alastair Reith,Jan Egebjerg,Gabrielle Ahlberg Hillert,Barbara Saba,Chris Min,Robert Umek,Joe Mather,Susan De Santi,Anke Post,Frank Boess,Kirsten Taylor,Igor Grachev,Andreja Avbersek,Pierandrea Muglia,Kaplana Merchant,Johannes Tauscher
DOI: https://doi.org/10.1016/j.parkreldis.2018.12.025
Abstract:Objective: To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). Background: Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. Design/methods: Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs. Results: PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs. Conclusions: LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.